International EECP Patient Registry -IEPR- Achieves Important Milestone; Registry to Provide New Data on Patients with Combined Angina and Heart Failure.

WESTBURY, N.Y. -- Vasomedical, Inc. (Nasdaq SC: VASO), a leader in the non-invasive treatment and management of cardiovascular diseases, today announced that Phase 2 of the International EECP(R) Patient Registry (IEPR-2) has met its enrollment target of 2,500 patients. IEPR-2 collects additional data to better characterize angina patients with coexisting heart failure and other conditions. Forty-seven EECP treatment centers across the United States participate in this voluntary registry, enrolling and following consecutive patients treated for angina pectoris.

Phase 1 of the IEPR enrolled an initial 5,000 angina patients between 1998 and 2001. According to data generated during Phase 1, approximately 80 percent of patients experience a reduction in angina following treatment with EECP therapy. IEPR data have led to 14 manuscripts published in peer-reviewed journals and 61 presentations at major national and international cardiology meetings during the past five years. Both phases of the IEPR are coordinated by the Epidemiology Data Center at the University of Pittsburgh, Graduate School of Public Health.

With the completion of enrollment for IEPR-2, physicians will gain additional information from the real-life experiences of cardiologists using EECP therapy to treat angina patients with heart failure. Patients are characterized by their demographics, medical history, symptom status and perceived quality of life immediately before EECP therapy, and at 6, 12 and 24-months post-therapy. The registry also captures data on medication use, emergency room visits, hospital admissions and subsequent invasive treatments, such as angioplasty and cardiac bypass surgery.

IEPR Medical Director Andrew Michaels, M.D., FACC, FAHA, said, "IEPR-2, like Phase 1, tracks the safety, efficacy and long-term outcomes of angina patients treated with EECP therapy, but also captures specific information regarding the status of those patients suffering with a heart failure co-morbidity. These data provide the medical community with richly detailed patient profiles and accurately depicts their response to EECP therapy. Without the registry, our understanding of this effective, non-invasive therapy would be far less comprehensive."

"We are extremely thankful for the generous voluntary efforts of all the participants in IEPR-2 and look forward to the many additional presentations and peer-reviewed articles these data will generate," said Vasomedical Vice President of Clinical, Regulatory and Quality Affairs Thomas Varricchione. "While controlled studies, such as our MUST-EECP (Multi-center Study of Enhanced External Counterpulsation) and PEECH (Prospective Evaluation of EECP in Congestive Heart Failure) trials, play an important role in understanding the benefits of our innovative therapy, the IEPR documents outcomes in real-life settings more often seen in daily practice. Both data sets are critically important in advancing our understanding of EECP therapy," added Thomas Varricchione.

About EECP(R) External Counterpulsation Therapy

Vasomedical's advanced, state-of-the-art EECP(R) external counterpulsation systems are comprised of an air compressor, a computer console, a set of cuffs and a treatment table. To receive treatment, patients lie down on the table and have their calves and lower and upper thighs wrapped in the cuffs. The system, which is synchronized to the individual patient's cardiac cycle, inflates the cuffs with air to create external pressure when the heart is resting (diastole) and deflates the cuffs just before the heart beats (systole). The system's action, which pulses counter to the heart's beating, increases blood flow to the heart muscle, decreases the heart's workload and creates a greater oxygen supply for the heart muscle while lowering the heart's need for oxygen.

Treatment is typically given in 35 one-hour-sessions over seven weeks; the benefits have been shown to persist for years. Researchers hypothesize that EECP(R) therapy may work by promoting the release of beneficial growth factors, by improving the neurohormonal milieu within blood vessels and by encouraging the proliferation of collateral blood vessels. Vasomedical's EECP(R) systems are the only counterpulsation devices shown in clinical studies published in major peer-reviewed journals to provide improvements in exercise capacity, peak oxygen consumption and quality of life.

About Vasomedical

Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting EECP(R) external counterpulsation systems based on the Company's proprietary technology. EECP(R) therapy is a non-invasive, outpatient therapy for the treatment of diseases of the cardiovascular system currently indicated for use in cases of angina, cardiogenic shock, acute myocardial infarction and congestive heart failure. The therapy serves to increase circulation in areas of the heart with less than adequate blood supply and may restore systemic vascular function. The Company provides hospitals, clinics and private practices with EECP(R) equipment, treatment guidance and a staff training and maintenance program designed to provide optimal patient outcomes. EECP(R) is a registered trademark for Vasomedical's enhanced external counterpulsation systems. Additional information is available on the Company's website at www.vasomedical.com.

Except for historical information contained in this report, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as "anticipated," "believes," "could," "estimates," "expects," "may," "plans," "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.